Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001907336 | SCV002121298 | uncertain significance | Jeune thoracic dystrophy; Nephronophthisis | 2022-09-01 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 1361055). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals affected with TTC21B-related conditions. This sequence change replaces asparagine, which is neutral and polar, with aspartic acid, which is acidic and polar, at codon 1089 of the TTC21B protein (p.Asn1089Asp). This variant is not present in population databases (gnomAD no frequency). |
Prevention |
RCV004734298 | SCV005363137 | uncertain significance | TTC21B-related disorder | 2024-08-27 | no assertion criteria provided | clinical testing | The TTC21B c.3265A>G variant is predicted to result in the amino acid substitution p.Asn1089Asp. To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |